Literature DB >> 18585512

Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy.

Sharie B Parks1, Jessica D Kushner, Deirdre Nauman, Donna Burgess, Susan Ludwigsen, Amanda Peterson, Duanxiang Li, Petra Jakobs, Michael Litt, Charles B Porter, Peter S Rahko, Ray E Hershberger.   

Abstract

BACKGROUND: Lamin A/C mutations are a well-established cause of dilated cardiomyopathy (DCM), although their frequency has not been examined in a large cohort of patients. We sought to examine the frequency of mutations in LMNA, the gene encoding lamin A/C, in patients with idiopathic (IDC) or familial dilated cardiomyopathy (FDC).
METHODS: Clinical cardiovascular data, family histories, and blood samples were collected from 324 unrelated IDC probands, of whom 187 had FDC. DNA samples were sequenced for nucleotide alterations in LMNA. Likely protein-altering mutations were followed up by evaluating additional family members, when possible.
RESULTS: We identified 18 protein-altering LMNA variants in 19 probands or 5.9% of all cases (7.5% of FDC; 3.6% of IDC). Of the 18 alterations, 11 were missense (one present in 2 kindreds), 3 were nonsense, 3 were insertion/deletions, and 1 was a splice site alteration. Conduction system disease and DCM were common in carriers of LMNA variants. Unexpectedly, in 6 of the 19 kindreds with a protein-altering LMNA variant (32%), at least one affected family member was negative for the LMNA variant.
CONCLUSIONS: Lamin A/C variants were observed with a frequency of 5.9% in probands with DCM. The novel observation of FDC pedigrees in which not all affected individuals carry the putative disease-causing LMNA mutation suggests that some protein-altering LMNA variants are not causative or that some proportion of FDC may be because of multiple causative factors. These findings warrant increased caution in FDC research and molecular diagnostics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585512      PMCID: PMC2527054          DOI: 10.1016/j.ahj.2008.01.026

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  27 in total

1.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling.

Authors:  J Ingles; A Doolan; C Chiu; J Seidman; C Seidman; C Semsarian
Journal:  J Med Genet       Date:  2005-10       Impact factor: 6.318

2.  Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).

Authors:  M Lanktree; H Cao; S W Rabkin; A Hanna; R A Hegele
Journal:  Clin Genet       Date:  2007-02       Impact factor: 4.438

3.  Clinical characteristics of 304 kindreds evaluated for familial dilated cardiomyopathy.

Authors:  Jessica D Kushner; Deirdre Nauman; Donna Burgess; Susan Ludwigsen; Sharie B Parks; George Pantely; Emily Burkett; Ray E Hershberger
Journal:  J Card Fail       Date:  2006-08       Impact factor: 5.712

Review 4.  Genetic causes of human heart failure.

Authors:  Hiroyuki Morita; Jonathan Seidman; Christine E Seidman
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 5.  Clinical and genetic issues in familial dilated cardiomyopathy.

Authors:  Emily L Burkett; Ray E Hershberger
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

6.  A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS.

Authors:  Jonas Denecke; Thomas Brune; Tobias Feldhaus; Horst Robenek; Christian Kranz; Richard J Auchus; Anil K Agarwal; Thorsten Marquardt
Journal:  Hum Mutat       Date:  2006-06       Impact factor: 4.878

7.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

8.  New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome.

Authors:  Aurélie Decaudain; Marie-Christine Vantyghem; Bruno Guerci; Annie-Claude Hécart; Martine Auclair; Yves Reznik; Hervé Narbonne; Pierre-Henri Ducluzeau; Bruno Donadille; Céleste Lebbé; Véronique Béréziat; Jacqueline Capeau; Olivier Lascols; Corinne Vigouroux
Journal:  J Clin Endocrinol Metab       Date:  2007-08-21       Impact factor: 5.958

9.  Compound mutations: a common cause of severe long-QT syndrome.

Authors:  Peter Westenskow; Igor Splawski; Katherine W Timothy; Mark T Keating; Michael C Sanguinetti
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

10.  High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics.

Authors:  J Peter van Tintelen; Robert M W Hofstra; Hilga Katerberg; Tom Rossenbacker; Ans C P Wiesfeld; Gideon J du Marchie Sarvaas; Arthur A M Wilde; Irene M van Langen; Eline A Nannenberg; Anneke J van der Kooi; Marian Kraak; Isabelle C van Gelder; Dirk Jan van Veldhuisen; Yvonne Vos; Maarten P van den Berg
Journal:  Am Heart J       Date:  2007-09-14       Impact factor: 4.749

View more
  99 in total

1.  Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy.

Authors:  Ana Morales; Thomas Painter; Ran Li; Jill D Siegfried; Duanxiang Li; Nadine Norton; Ray E Hershberger
Journal:  Circulation       Date:  2010-05-10       Impact factor: 29.690

Review 2.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 3.  Cardiovascular genetic medicine: evolving concepts, rationale, and implementation.

Authors:  Ray E Hershberger
Journal:  J Cardiovasc Transl Res       Date:  2008-05-20       Impact factor: 4.132

4.  Abnormal p38α mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation.

Authors:  Antoine Muchir; Wei Wu; Jason C Choi; Shinichi Iwata; John Morrow; Shunichi Homma; Howard J Worman
Journal:  Hum Mol Genet       Date:  2012-07-05       Impact factor: 6.150

5.  Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy.

Authors:  Marwan M Refaat; Steven A Lubitz; Seiko Makino; Zahid Islam; J Michael Frangiskakis; Haider Mehdi; Rebecca Gutmann; Michael L Zhang; Heather L Bloom; Calum A MacRae; Samuel C Dudley; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Barry London; Patrick T Ellinor
Journal:  Heart Rhythm       Date:  2011-10-17       Impact factor: 6.343

6.  Left ventricular noncompaction in a family with lamin A/C gene mutation.

Authors:  John J Parent; Jeffrey A Towbin; John L Jefferies
Journal:  Tex Heart Inst J       Date:  2015-02-01

Review 7.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy.

Authors:  Ray E Hershberger; Jill D Siegfried
Journal:  J Am Coll Cardiol       Date:  2011-04-19       Impact factor: 24.094

8.  Late onset sporadic dilated cardiomyopathy caused by a cardiac troponin T mutation.

Authors:  Ana Morales; Jose Renato Pinto; Jill D Siegfried; Duanxiang Li; Nadine Norton; Mark Hofmeyer; Marta Vallin; Azorides R Morales; James D Potter; Ray E Hershberger
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

Review 9.  Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals.

Authors:  Elham Kayvanpour; Farbod Sedaghat-Hamedani; Ali Amr; Alan Lai; Jan Haas; Daniel B Holzer; Karen S Frese; Andreas Keller; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2016-08-30       Impact factor: 5.460

10.  Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy.

Authors:  Chad Brodt; Jill D Siegfried; Mark Hofmeyer; Jose Martel; Evadnie Rampersaud; Duanxiang Li; Ana Morales; Ray E Hershberger
Journal:  J Card Fail       Date:  2013-04       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.